33106 Federal Register / Vol. 66, No. 119 / Wednesday, June 20, 2001 / Notices

demonstrated in plaque reduction

assays that 5-substituted uracils (bromo,

iodo, and bromovinyl) attached to a

bicyclo[3.1.0]hexane template are thirty

times more potent than acyclovir against

HSV–1 and HSV–2.

Dated: June 11, 2001.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer,

National Institutes of Health.

[FR Doc. 01–15459 Filed 6–19–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing: Cloned

Hepatitis C Virus (HCV) Genomes,

Chimeras, and Derivatives Thereof

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by

contacting Peter A. Soukas, J.D., at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7056 ext. 268; fax: 301/402–0220;

e-mail: soukasp@od.nih.gov. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

SUPPLEMENTARY INFORMATION: Hepatitis

C virus (HCV) is a single stranded RNA

virus responsible for the majority of

non-A non-B hepatitis. Hepatitis C virus

(HCV) has a worldwide distribution and

is a major cause of liver cirrhosis and

hepatocellular carcinoma in the U.S.,

Europe, and Japan. For this reason,

development of a vaccine against

hepatitis C is of great importance. The

present inventions claim full-length

sequences of HCV, HCV chimeras and

HCV derivatives, and methods for using

these full-length sequences for a variety

of therapeutic and diagnostic

applications, including vaccines.

Cloned Genomes of Infectious Hepatitis

C Virus and Uses Thereof

Masayuki Yanagi, Jens Bukh, Suzanne

U. Emerson, Robert H. Purcell (NIAID)

Serial No. 09/014,416 filed 27 Jan 1998,

issued as U.S. Patent 6,153,421 on 28

Nov 2000; Serial No. 09/662,454 filed

14 Sep 2000; Canadian Application

2295552; Australian Application

84889/98; European Application

98935702.5

The current invention provides

nucleic acid sequences comprising the

genomes of infectious hepatitis C

viruses (HCV) of genotype 1a and 1b. It

covers the use of these sequences, and

polypeptides encoded by all or part of

the sequences, in the development of

vaccines and diagnostic assays for HCV

and the development of screening

assays for the identification of antiviral

agents for HCV. Additional information

can be found in Yanagi et al., (1997)

Proc. Natl. Acad. Sci., USA 94, 8738–

8743 and Yanagi et al. (1998) Virology

244, 151–172.

Cloned Genome of Infectious Hepatitis

C Virus of Genotype 2a and Uses

Thereof

Jens Bukh, Masayuki Yanagi, Robert H.

Purcell, Suzanne U. Emerson (NIAID)

DHHS Reference No. E–100–99/0, U.S.

S/N 60/137,693 filed 04 Jun 1999;

DHHS Reference No. E–100–99/1,

PCT/US00/15466 filed 02 Jun 2000

The current invention provides a

nucleic acid sequence comprising the

genome of infectious hepatitis C viruses

(HCV) of genotype 2a. The encoded

polyprotein differs from those of the

infectious clones of genotypes 1a and 1b

(U.S. Patent 6,153,421) by

approximately thirty (30) percent. It

covers the use of this sequence and

polypeptides encoded by all or part of

the sequence, in the development of

vaccines and diagnostic assays for HCV

and the development of screening

assays for the identification of antiviral

agents for HCV. Additional information

can be found in Yanagi et al. (1999),

Virology 262, 250–263.

HCV/BVDV Chimeric Genomes and

Uses Thereof

Jae-Hwan Nam, Jens Bukh, Robert H.

Purcell, Suzanne U. Emerson (NIAID)

DHHS Reference No. E–102–99/0, U.S.

S/N 60/137,817 filed 04 June 1999;

DHHS Reference No. E–102–99/1,

PCT/US00/15527 filed 02 Jun 2000

The current invention provides

nucleic acid sequences comprising

chimeric viral genome of hepatitis C

Virus (HCV) and bovine viral diarrhea

viruses (BVDV). The chimeric viruses

are produced by replacing the structural

region or a structural gene of an

infectious BVDV clone with the

corresponding region or gene of an

infectious HCV. It covers the use of

these sequences and polypeptides

encoded by all or part of the sequences

in the development of vaccines and

diagnostic assays for HCV and the

development of screening assays for the

identification of antiviral agents for

HCV.

Infectious cDNA Clone of GB Virus B

and Uses Thereof

Jens Bukh, Masayuki Yanagi, Robert H.

Purcell, Suzanne U. Emerson (NIAID)

DHHS Reference No. E–173–99/0, U.S.

S/N 60/137,694 filed 04 Jun 1999;

DHHS Reference No. E–173–99/1,

PCT/US00/15293 filed 02 Jun 2000

The current invention provides

nucleic acid sequences comprising the

genomes of infectious GB virus B, the

most closely related member of the

Flaviviridae to hepatitis C virus (HCV).

It also covers chimeric GBVB–HCV

sequences and polypeptides for use in

the development of vaccines and

diagnostic assays for HCV and the

development of screening assays for the

identification of antiviral agents for

HCV. Additional information can be

found in Bukh et al. (1999), Virology

262, 470–478.

Dated: June 11, 2001.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer,

National Institutes of Health.

[FR Doc. 01–15462 Filed 6–19–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Office of the Secretary

White House Commission on

Complementary and Alternative

Medicine Policy; Notice of Meeting

Pursuant to section 10(a) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is given of a meeting of the White House

Commission on Complementary and

Alternative medicine Policy.

The purpose of this public meeting is

to convene the Commission to discuss

possible Federal policy regarding

complementary and alternative

medicine (CAM). The main focus of the

meeting is the development and

discussion of draft recommendations

that may be included in the Interim and